
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Access to a financial planner
Otonomy is a biotechnology business based in the US. Otonomy shares (OTIC) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.08 – the same closing value as a week prior. Otonomy employs 51 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Latest market close | $0.08 |
---|---|
52-week range | $0.00 - $0.00 |
50-day moving average | $0.11 |
200-day moving average | $0.36 |
Wall St. target price | $9.00 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-0.06 |
Historical closes compared with the close of $0.077 from 2025-01-29
1 week (2025-01-27) | N/A |
---|---|
1 month (2025-01-03) | N/A |
3 months (2024-11-03) | N/A |
6 months (2024-08-03) | N/A |
1 year (2024-02-03) | N/A |
---|---|
2 years (2023-02-03) | N/A |
3 years (2022-02-04) | 2.01 |
5 years (2020-02-06) | 3.22 |
Gross profit TTM | $-245,000 |
---|---|
Return on assets TTM | -38.12% |
Return on equity TTM | -118.86% |
Profit margin | 0% |
Book value | $0.38 |
Market Capitalization | $582,482 |
TTM: trailing 12 months
We're not expecting Otonomy to pay a dividend over the next 12 months.
Over the last 12 months, Otonomy's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Otonomy's is 1.5717. This would suggest that Otonomy's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Otonomy, Inc. , a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Find out more about this component of your brokerage account and how you can use this cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.